67 reports

Mitochondrial Disease Therapies Market, 2019-2030 ##.

  • Pathology
  • Therapy
  • United States
  • World

Neoantigen Targeted Therapies Market, 2019-2030 ##.

  • Targeted Therapy
  • Therapy
  • United States
  • World
  • Market Size

Global T-Cell (CAR-T TCR and TIL) Therapy Market (##th Edition) 2019-2030 ##.

  • Immunotherapy
  • Medical Biotechnology
  • Therapy
  • United States

CAR-T Therapies Market (##nd Edition), 2019-2030 ##.

  • Immunotherapy
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy
  • United States

CAR-T Therapies Market, 2018-2030 ##.

  • Medical Biotechnology
  • Therapy
  • China
  • United States

PATIENTS RECEIVED THE THERAPY AS SPLIT DOSE INFUSIONS OF ##-##X## OR ##-##X## CELLS OVER THREE DAYS (##% ON DAY ##, ##% ON DAY ##, AND ##% ON DAY ##).

  • Therapy
  • United States
  • Affimed Therapeutics AG
  • Amgen Inc.
  • Celgene Corporation

THE ENTIRE PROCESS, FROM CELL COLLECTION TO INJECTION OF THE THERAPY, TAKES ABOUT ##-## DAYS DEPENDING ON THE PATIENT' S LOCATION.

  • Hospital
  • Therapy
  • United States
  • Erytech Pharma SA
  • Neurotech Pharmaceuticals, Inc.

THERAPIES.

  • Therapy
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Resverlogix Corp.
  • Vifor Pharma

MIHAELA DRUTA NY-ESO-## T CELLS Name TCR Therapy NY-ESO-## T CELLS NY-ESO-## T CELLS NY-ESO-## T CELLS NY-ESO-## T CELLS NY-ESO-## T CELLS NY-ESO-## T CELLS NY-ESO-## T CELLS NY-ESO-## T CELLS NY-ESO-## T CELLS

  • Therapy
  • Company
  • Market Size
  • Juno Therapeutics Inc.
  • Novartis AG

ONE OF OUR FIRST PRODUCTS IS A CELL-BASED THERAPEUTIC FOR THE TREATMENT OF SICKLE CELL DISEASE.

  • Therapy
  • World
  • Company
  • Market Size
  • Lonza Group Ltd

IN THE BEGINNING, THE TREATMENT COSTS FOR IMMUNO-ONCOLOGY DRUGS WERE CLOSE TO USD ## MILLION PER YEAR PER PATIENT.

  • Therapy
  • North America
  • United States
  • World
  • Demand

IT IS THEREFORE POSSIBLE TO USE HSV VECTORS FOR THE TREATMENT OF DISORDERS CAUSED BY MORE THAN ONE DEFECTIVE GENE.

  • Therapy
  • Market Size
  • Supply
  • Lonza Group Ltd
  • Sanofi S.A.

The patients were randomized to one of the five treatment groups (## mg, ## mg, ## mg, ## mg and placebo).

  • Therapy
  • North America
  • United States
  • Eli Lilly & Co.
  • Grunenthal GmbH

One peptide molecule (TXA##) is being evaluated for the treatment of DMD.

  • Therapy
  • North America
  • United States
  • Ironwood Pharmaceuticals, Inc.
  • Novo Nordisk Group

ACTIVE INDUSTRY PLAYERS FIGURE ##. ## MICROBIOME THERAPEUTICS: ACTIVE INDUSTRY PLAYERS ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Phase I Phase I (planned) Preclinical Discovery Phase (Unknown) ## ##.

  • Therapy
  • North America
  • United States
  • Market Size
  • MicroBiome Therapeutics LLC

Further, ##% of the therapies target more than one of these diseases. ##.

  • Therapy
  • United States

THE TRIAL ENROLLED ## PATIENTS WHO HAD REPORTED FAILURE TO AT LEAST ONE PRIOR STANDARD THERAPY.

  • Therapy
  • North America
  • United States
  • AstraZeneca PLC
  • Novartis AG

SUMATRIPTAN SUCCINATE, A SEROTONIN-## RECEPTOR AGONIST, IS INDICATED FOR THE TREATMENT OF THIS CLINICAL CONDITION.

  • Neurological Disorder
  • Therapy
  • World
  • Forecast
  • Antares Pharma, Inc.

Cognitive Behavioral Therapy ##. ##. ##.

  • Therapy
  • APAC
  • United States
  • World
  • Market Size

July 2017: Key advantages: One time treatment ## Source: http:/ / ir. sparktx. com/ phoenix. zhtml?

  • Therapy
  • United States
  • Alcon, Inc.
  • Allergan plc
  • Novartis AG

THE MEDIAN TREATMENT DURATION WAS ONE TREATMENT CYCLE (RANGING BETWEEN ## AND ##).

  • Therapy
  • North America
  • United States
  • Ablynx NV
  • Amgen Inc.

IN CASE OF PATIENT-SPECIFIC THERAPIES, WHERE ONE BATCH IS PRODUCED FOR ONE PATIENT, THE MANUFACTURING PROCESS CANNOT BE SCALED-UP.

  • Therapy
  • North America
  • United States
  • Argos Therapeutics, Inc.
  • Lonza Group Ltd

SIMILAR IMPROVEMENT WAS SEEN IN DAS##-CRP SCORE WITHIN ONE WEEK OF TREATMENT.

  • Therapy
  • North America
  • United States
  • AbbVie Inc.
  • Astellas Pharma Inc.

IN PATIENTS IN ARM ## (GROUP ##), ARM ## (GROUP ##), ARM ## AND ARM ## OF THE STUDY, THE MEAN VISUAL ACUITY FROM BASELINE POST ## WEEKS OF THE TREATMENT WAS ##. ## LETTERS, ##. ## LETTERS, ##. ## LETTERS AND ##. ## LETTERS, RESPECTIVELY.

  • Therapy
  • United States
  • Allergan plc
  • Molecular Partners AG
  • Roche Group

THERE IS ONLY ONE DRUG, DIFICID, THAT WAS APPROVED POST 2010 (IN MAY 2011) FOR THE TREATMENT OF CDIS.

  • Therapy
  • United States
  • Cempra, Inc.
  • CyDex Pharmaceuticals, Inc.
  • Melinta Therapeutics, Inc.

One patient showed stable disease and continued the ivosidenib treatment.

  • Therapy
  • North America
  • United States
  • Celgene Corporation
  • Polaris Pharmaceuticals, Inc.

IN JUNE 2016, THE EUROPEAN COMMISSION APPROVED TYSABRI FOR THE TREATMENT OF RRMS PATIENTS WITH HIGH DISEASE ACTIVITY DESPITE A FULL AND ADEQUATE COURSE OF TREATMENT WITH AT LEAST ONE DISEASE MODIFYING THERAPY (DMT).

  • Therapy
  • North America
  • United States
  • World
  • West Pharmaceutical Services, Inc.

TAKEDA' S NINLARO, APPROVED IN 2015, IS THE FIRST AND ONLY ORAL SECOND GENERATION PROTEASOME INHIBITOR FOR THE TREATMENT OF MM PATIENTS WITH AT LEAST ONE PRIOR LINE OF TREATMENT.

  • Therapy
  • United States
  • Almac Discovery Ltd.
  • Amgen Inc.
  • Celgene Corporation

THE POST-PRANDIAL GLUCOSE LEVEL WAS MEASURED AT BASELINE BEFORE TREATMENT, AS WELL AS AFTER ONE WEEK OF THERAPY.

  • Therapy
  • North America
  • United States
  • Boehringer Ingelheim GmbH
  • Sanofi S.A.

term=NCT##& rank=## ## In combination with carfilzomib and dexamethasone ## Prior treatment with ## to ## lines of therapy ## Source: https:/ / clinicaltrials. gov/ ct##/ show/ NCT##?

  • Therapy
  • North America
  • United States
  • Mirati Therapeutics, Inc.
  • Novartis AG